Stroke Risk Increased With Evista Which Reduces Breast Cancer Risk

Jamie Sheller

Attorney
(866) 735-1102 Ext 475

0 CommentsPrint ArticleSubscribe

According to a study reported in the July 13 issue of the New England Journal of Medicine, compared with a placebo, Evista provided a 44% reduction in the risk of invasive breast cancer. However, along with the reduced breast cancer risk, came a 49% increase in the relative risk of fatal stroke. The study included over 10,000 postmenopausal women. Evista is manufactured by Lilly. Though Evista's current approved use is for treatment and prevention of osteoporosis in postmenopausal women, Lilly recently indicated that it would seek FDA approval for the drug's use to prevent cancer.